
United Therapeutics (UTHR) Stock Forecast & Price Target
United Therapeutics (UTHR) Analyst Ratings
Bulls say
United Therapeutics is poised for growth and success with its drug therapies that target the prostacyclin pathway and its dominant position in the PAH market. The positive TETON-1 and TETON-2 data support the use of Tyvaso as monotherapy or in combination therapy for IPF, while the company's disciplined operating expenses and promising pipeline add to its strong outlook for the future. With a diverse portfolio of commercial and potential products, United Therapeutics is well-positioned to continue its success and deliver positive results for both patients and investors.
Bears say
United Therapeutics is heavily reliant on sales of Tyvaso DPI and its other treatments for PAH, with limited diversification in terms of revenue sources. The success of its TETON-1 and TETON-2 trials may lead to wider adoption of Tyvaso as a standard of care, but concerns around cough, sore throat, and adherence to the inhaled regimen may limit its usage. The company's future potential depends on the success and regulatory support of its pipeline products, including nebulized Tyvaso and TRESMI, which may face challenges in the competitive and highly regulated market for PAH treatments.
This aggregate rating is based on analysts' research of United Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
United Therapeutics (UTHR) Analyst Forecast & Price Prediction
Start investing in United Therapeutics (UTHR)
Order type
Buy in
Order amount
Est. shares
0 shares